JPWO2020181102A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020181102A5
JPWO2020181102A5 JP2021548244A JP2021548244A JPWO2020181102A5 JP WO2020181102 A5 JPWO2020181102 A5 JP WO2020181102A5 JP 2021548244 A JP2021548244 A JP 2021548244A JP 2021548244 A JP2021548244 A JP 2021548244A JP WO2020181102 A5 JPWO2020181102 A5 JP WO2020181102A5
Authority
JP
Japan
Prior art keywords
crispr
activity
cas effector
polypeptide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522650A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021214 external-priority patent/WO2020181102A1/fr
Publication of JP2022522650A publication Critical patent/JP2022522650A/ja
Publication of JPWO2020181102A5 publication Critical patent/JPWO2020181102A5/ja
Pending legal-status Critical Current

Links

JP2021548244A 2019-03-07 2020-03-05 Crispr-casエフェクターポリペプチド及びその使用方法 Pending JP2022522650A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815179P 2019-03-07 2019-03-07
US62/815,179 2019-03-07
PCT/US2020/021214 WO2020181102A1 (fr) 2019-03-07 2020-03-05 Polypeptides effecteurs crispr-cas et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
JP2022522650A JP2022522650A (ja) 2022-04-20
JPWO2020181102A5 true JPWO2020181102A5 (fr) 2023-03-13

Family

ID=72338076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548244A Pending JP2022522650A (ja) 2019-03-07 2020-03-05 Crispr-casエフェクターポリペプチド及びその使用方法

Country Status (5)

Country Link
US (1) US20210380957A1 (fr)
EP (1) EP3935155A4 (fr)
JP (1) JP2022522650A (fr)
CN (1) CN114040971A (fr)
WO (1) WO2020181102A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660419B2 (en) * 2016-12-15 2020-05-26 Elc Management Llc Packaged skin treatment composition and method
EP4222167A1 (fr) 2020-09-30 2023-08-09 Nobell Foods, Inc. Protéines de lait recombinantes et compositions les comprenant
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
EP4347818A2 (fr) 2021-06-01 2024-04-10 Arbor Biotechnologies, Inc. Systèmes d'édition de gènes comprenant une nucléase crispr et leurs utilisations
WO2024006824A2 (fr) * 2022-06-28 2024-01-04 Mammoth Biosciences, Inc. Protéines effectrices, compositions, systèmes et leurs procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605709B1 (en) * 1999-04-09 2003-08-12 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
CA2537273A1 (fr) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Procede de production de proteines de fusion dans le lait de mammiferes transgeniques
CA3009190A1 (fr) * 2015-12-29 2017-07-06 Monsanto Technology Llc Nouvelles transposases associees a crispr et leurs utilisations
AU2017257274B2 (en) * 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
US11692184B2 (en) * 2017-05-16 2023-07-04 The Regents Of The University Of California Thermostable RNA-guided endonucleases and methods of use thereof
GB201712733D0 (en) * 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells

Similar Documents

Publication Publication Date Title
AU2016316845B2 (en) Engineered CRISPR-Cas9 nucleases
US10093910B2 (en) Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) Engineered CRISPR-Cas9 nucleases
JP6940117B2 (ja) オンターゲットおよびオフターゲットの多標的システムを用いた標的特異的ヌクレアーゼをスクリーニングするための方法およびその利用
US10767193B2 (en) Engineered CAS9 systems for eukaryotic genome modification
JP2023153907A (ja) Rna標的化方法および組成物
US10822606B2 (en) Optimized small guide RNAs and methods of use
JP7379160B2 (ja) CRISPR-Cpf1を使用する誘導性で調整可能な多重ヒト遺伝子制御
JP2017018125A5 (fr)
JP2021121205A5 (fr)
GB2595606A (en) CRISPR-Cas effector polypeptides and methods of use thereof
JP2015503535A5 (fr)
CA2956224A1 (fr) Proteines cas9 comprenant des inteines dependant de ligands
RU2020105703A (ru) Специфические для мишени варианты, связанные с crispr
JP2023156365A5 (fr)
AR125191A1 (es) Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso
JPWO2020181102A5 (fr)
JP7249620B2 (ja) 核酸結合因子
WO2023207607A1 (fr) Mutant de désaminase, composition et procédé de modification d'adn mitochondrial
JP6874996B2 (ja) 人工rna制限酵素
JP2022526695A (ja) 遺伝子編集における非意図的な変異の阻害
JPWO2021007563A5 (fr)
WO2022187278A1 (fr) Systèmes de détection et d'analyse d'acides nucléiques
AR123483A1 (es) Enzimas modificadoras de adn y fragmentos activos y variantes de las mismas y métodos de uso
WO2023057880A1 (fr) Protéines de fusion à base de crispr/cas9 pour moduler l'expression génique et procédés d'utilisation